Skip to content

Geron GERN Long-Term Debt

Long-Term Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$42.15B-8.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$100M+108%
Celcuity logo
CelcuityCELC
$137.87M+30.9%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.32B-19.0%
Gilead Sciences logo
Gilead SciencesGILD
$20.86B-5.8%
Biogen logo
BiogenBIIB
$6.29B+38.2%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's long-term debt?
Geron (GERN) reported long-term debt of $119.83M in Q1 2026.
How has Geron's long-term debt changed year-over-year?
Geron's long-term debt increased by 0.9% year-over-year, from $118.73M to $119.83M.
What is the long-term trend for Geron's long-term debt?
Over 5 years (2020 to 2025), Geron's long-term debt has grown at a 37.8% compound annual growth rate (CAGR), from $24.04M to $119.55M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.